T-Guard

DRUG4 trials

Sponsors

Philikos B.V., Xenikos

Conditions

Graft vs Host DiseaseSteroid-Refractory Acute Graft Versus Host Diseasediffuse cutaneous systemic sclerosis

Phase 1

Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD

CompletedNCT02027805

XenikosGraft vs Host Disease

Start: 2014-03-05End: 2016-11-03Updated: 2017-06-06

T-Guard against Autoreactive T cells in Systemic sclerosis: Erasion and Resolution (TASER)

RecruitingCTIS2024-517283-28-00

Philikos B.V.diffuse cutaneous systemic sclerosis

Start: 2025-04-29Target: 13Updated: 2025-09-11

Phase 3

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

TerminatedNCT04128319

XenikosSteroid-Refractory Acute Graft Versus Host Disease

Start: 2019-11-21End: 2020-02-17Updated: 2021-12-16

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)

TerminatedNCT04934670

XenikosSteroid-Refractory Acute Graft Versus Host Disease

Start: 2022-06-16End: 2023-01-19Updated: 2024-08-27

Related Papers

Antibodies to watch in 2020.

2020-01-01328 citations

A Phase I/II Study on the Anti-CD3/CD7 Immunotoxin Combination (T-GuardTM) for the Treatment of Steroid-Refractory Acute Gvhd

Blood2017-12-071 citations